Biocon's shares experienced a 4% decline, reaching an intra-day low of ₹340.7 per share on the National Stock Exchange (NSE) with 9.58 million shares traded. This drop occurred while the NSE Nifty50 index fell by 0.13%. Chairperson Kiran Mazumdar-Shaw stated that Biocon is positioning itself as a leader in the insulin market, especially as larger competitors shift focus to GLP-1 therapies. She noted that while GLP-1 drugs are promising, they have limitations for Type-1 and late-stage Type-2 diabetics, ensuring the continued necessity of insulin. Biocon aims to maximize value through strategic capital allocation, focusing on insulin production where margins are favorable compared to GLP-1 drugs. New MD and CEO Shreehas Tambe underscored the company's commitment to making life-saving drugs affordable and targeting growth in diabetes care, projecting a 45% increase in global diabetes cases over the next decade, reaching 850 million patients.